2019 CYIR Finalized

27 ASTHMA Njira Lugogo, MD University of Michigan Ann Arbor, MI MONDAY, MAY 20 ASTHMA NEW THERAPEUTIC APPROACHES TO MILD ASTHMA Bateman ED, Reddel HK, O’Byrne PM, Barnes PJ, Zhong N, Keen C, Jorup C, Lamarca R, Siwek-Posluszna A, FitzGerald JM. As-Needed Budesonide-Formoterol ver- sus Maintenance Budesonide in Mild Asthma. N Engl J Med. 2018;378(20):1877-87. O’Byrne PM, FitzGerald JM, Bateman ED, Barnes PJ, Zhong N, Keen C, Jorup C, Lamarca R, Ivanov S, Reddel HK. Inhaled Combined Budesonide-Formoterol as Needed in Mild Asthma. N Engl J Med. 2018;378(20):1865-76. Epub 2018/05/17. doi: 10.1056/NEJMoa1715274. PubMed PMID: 29768149. Summary The treatment paradigm for the management of mild asthma has not changed in decades. Both the GINA and NAEPP guidelines recommend a stepwise approach to asthma therapy with the use of inhaled corticosteroids as maintenance therapy for patients with GINA step 2/3 dis- ease. This pair of multicenter, randomized, double blind, placebo-controlled trials in patients with controlled step 2 or uncontrolled step 3 asthma were designed to determine whether all patients with mild persistent asthma require daily maintenance inhaled steroid (ICS) therapy or whether intermittent inhaled steroid/long acting beta agonist (ICS/ LABA) therapy is an acceptable alternative. Furthermore, the authors were interested in shifting the treatment para- digm with regards to rescue bronchodilator therapy by introducing the concept of using ICS/LABA as relivers. These are important clinical questions given the increased recognition that up to 50% of patients with mild asthma have no evidence of underlying eosinophilic inflammation based on sputum differential cell counts and therefore are unlikely to benefit from inhaled corticosteroids. In this subgroup of patients administration of a bronchodilator would be immensely important in ameliorating asthma symptoms. In addition, the currently accepted approach of treating acute asthma symptoms with a bronchodilator without concomitant anti-inflammatory therapy should be considered as most acute symptoms likely result from both inflammation and bronchoconstriction. Comments 1. Daily maintenanance therapy with budesonide resulted in bet- ter asthma symptom control and change in baseline FEV1 as compared to as needed ICS/LABA. 2. ICS/LABA was superior to as needed terbutaline but inferior to maintenance budesonide in achieving asthma control. 3. As needed ICS/LABA therapy was non-inferior to budesonide in reducing asthma exacerbations and time to first asthma exac- erbation in both studies. 4. Importantly, as needed ICS/LABA and ICS were both superior to terbutaline in controlling asthma exacerbations indicating that the concept of using anti-inflammatory medications with relievers is crucial to reducing exacerbation risk in patients with asthma. 5. Not suprisingly, patients receiving as needed ICS/LABA therapy had a significant reduction in inhaled steroid exposure in com- parison to the daily ICS group. 6. This study offers an alternative approach to patients with mild asthma particularly those that experience exacerbations but few asthma symptoms and no lung function impairment. We may be able to offer both bronchodilation with concomitant anti-inflammatory therapy for these patients while concurrently sparing them from unnecessary exposure to inhaled steroids at high doses. THRESHOLDS FOR TOXICITY WITH ORAL STEROID EXPOSURE MUCH LOWER THAN PREDICTED Price DB, Trudo F, Voorham J, Xu X, Kerkhof M, Ling Zhi Jie J, Tran TN. Adverse outcomes from initiation of systemic corticosteroids for asthma: long-term obser- vational study. J Asthma Allergy. 2018;11:193-204. Epub 2018/09/15. doi: 10.2147/JAA.S176026. PubMed PMID: 30214247; PMCID: PMC6121746. Summary Exposure to oral corticosteroids(OCS) is very high in patients with asthma and other respiratory diseases. Even patients will mild disease receive OCS for treatment of acute exacerbations. Respiratory illnesses present the most common reason for OCS prescription and patients with severe asthma can receive multiple courses of OCS per year, some as many as 4-6 times per year. There is well- established data on OCS toxicity and it is well accepted that OCS causes multiple co-morbidities with long term exposure. However, little is known about the safety thresh- old for OCS and, therefore, clinicians are unable to make determinations about risk benefit ratio of therapy with OCS.

RkJQdWJsaXNoZXIy MTM1ODMw